The uncharted role of HER2 mutant alleles in breast cancer

Somatic HER2 mutations are a novel class of therapeutic targets across different cancer types. Treatment with the tyrosine kinase inhibitor (TKI) neratinib as a single agent continues to be evaluated in HER2-mutant metastatic disease. However, responses are heterogeneous, with frequent early progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalra, Rashi, Lim, Bora, Ellis, Matthew J., Kavuri, Shyam M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2023
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624202/
https://www.ncbi.nlm.nih.gov/pubmed/37921670
http://dx.doi.org/10.18632/oncotarget.28489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624202/
https://www.ncbi.nlm.nih.gov/pubmed/37921670
http://dx.doi.org/10.18632/oncotarget.28489

Ejemplares similares